

Annovis Bio, Inc. (ANVS)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001477845

Annovis Bio, Inc. ANVS; healthcare		
Grade	None 3 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$21.1M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	dilution, short runway, thin data, degenerate inputs not computable: distress, fortress balance sheet	
Inputs computable	3 of 14	
Graded from	filings received through Mar 13, 2026 210 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026	
Last close	\$1.18 2026-10-08; market equity \$50.3M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 13, 2026

We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins - APP/A? ("APP"), tau/phospho-tau ("tau"), ?-Synuclein ("?SYN") and TDP43 - that are some of the main causes of neurodegeneration.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 23.7						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(18.5%)	(6.6%)	23.7	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		not computable	(0.31)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		not computable	2.96x			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Growth and financing, sleeve percentile 76.4						
Revenue growth, three-year compound		not computable	10.0%			current value must be positive and the base must exceed \$100,000
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(16.4%)	2.1%	77.8	704	2025-12-31
Net share issuance, one year		45.5%	2.5%	75.0	634	2026-03-12

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 45.5%
Short runway	cash runway is 5.2 months
Thin data	3 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(16.9%)	8.0%	33
Distance from 52-week high	(77.1%)	(31.4%)	9
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	(0.09)	0.28	7
Sales to price	0.00	0.31	0
Composite equity issuance, five years	181.4%	20.3%	87
Relative strength against the sector, log excess return	(0.40)	(0.14)	33

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$18.7M
Operating cash flow, four quarters	-\$43.3M
Months of runway	5.2
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$1.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$28.9M	2025-12-31	2026-03-13	10-K	0001104659-26-027751
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$25.6M	2025-12-31	2026-03-13	10-K	0001104659-26-027751
3	assets	us-gaap:Assets	\$21.1M	2025-12-31	2026-03-13	10-K	0001104659-26-027751
4	assets	us-gaap:Assets	\$13.9M	2024-12-31	2026-03-13	10-K	0001104659-26-027751
5	current assets	us-gaap:AssetsCurrent	\$10.2M	2023-12-31	2024-03-29	10-K	0001558370-24-004393
6	current liabilities	us-gaap:LiabilitiesCurrent	\$4.3M	2023-12-31	2025-03-21	10-K	0001558370-25-003482
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$110.3M	2023-12-31	2025-03-21	10-K	0001558370-25-003482
8	operating income	us-gaap:OperatingIncomeLoss	-\$45.0M	2023-12-31	2025-03-21	10-K	0001558370-25-003482
9	book equity	us-gaap:StockholdersEquity	-\$7.8M	2023-12-31	2026-03-13	10-K	0001104659-26-027751
10	assets	us-gaap:Assets	\$10.2M	2023-12-31	2025-03-21	10-K	0001558370-25-003482
11	liabilities	us-gaap:Liabilities	\$18.0M	2023-12-31	2025-03-21	10-K	0001558370-25-003482
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2025-12-31	2026-03-13	10-K	0001104659-26-027751
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2024-12-31	2025-03-21	10-K	0001558370-25-003482
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2023-12-31	2024-03-29	10-K	0001558370-24-004393

15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2022-12-31	2023-03-31	10-K	0001104659-23-040275
16	assets	us-gaap:Assets	\$36.0M	2022-12-31	2024-03-29	10-K	0001558370-24-004393
17	shares outstanding	dei:EntityCommonStockSharesOutstanding	28,355,262	2026-03-12	2026-03-13	10-K	0001104659-26-027751
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	19,486,231	2025-03-18	2025-03-21	10-K	0001558370-25-003482